文献速递胸部肿瘤支持与姑息治疗

美国国家医疗系统中黑人与白人患者免疫检查点抑制剂疗效与安全性的回顾性队列研究

Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study.
PubMed 文献 · Lancet Oncol · 2024-11-14

该回顾性队列研究基于美国退伍军人健康管理局系统数据,纳入2010年1月1日至2023年12月31日接受PD-1、PD-L1、CTLA-4或LAG-3抑制剂治疗的26 398例患者,比较黑人与白人患者的疗效与安全性。结果显示黑人患者治疗中断时间更长、总生存略有改善,免疫相关不良事件风险降低。

要点

  • 黑人患者较白人患者治疗中断时间更长(调整HR 0·91),总生存略有改善(调整HR 0·95)。
  • 黑人患者所有级别免疫相关不良事件风险降低(调整HR 0·75)。
  • 黑人患者需全身类固醇治疗的免疫相关不良事件及导致永久停药的风险均降低。

核心结论

  • 在美国退伍军人健康管理局系统中,黑人患者与白人患者相比免疫检查点抑制剂疗效相似且毒性更低,可能反映治疗指数的重要差异。
  • 黑人患者毒性降低的发现需进一步研究以评估其普遍性。

研究设计与样本

  • 回顾性队列研究,基于美国退伍军人健康管理局系统企业数据仓库电子病历,纳入2010年1月1日至2023年12月31日接受PD-1、PD-L1、CTLA-4或LAG-3抑制剂治疗的自认为非西班牙裔黑人/非洲裔美国人或非西班牙裔白人患者。
  • 共识别26 398例患者,其中黑人4943例(18·7%),白人21 455例(81·3%),女性895例(3·4%),男性25 503例(96·6%),非小细胞肺癌11 859例(45%),接受PD-1或PD-L1抑制剂者26 045例(98·7%)。
  • 安全性分析从随机抽取的1000例黑人患者和1000例白人患者中,按基线特征1:1精确匹配无放回匹配出892对,经人工病历审查排除未接受免疫检查点抑制剂治疗或随访不足者,最终1710例(黑人862例,白人848例)纳入安全性分析。
  • 疗效结局采用倾向加权Cox回归(稳健标准误)在全免疫检查点抑制剂治疗队列中评估;安全性结局采用多变量Cox回归在随机匹配样本中分析,调整基线特征。

主要发现

  • 截至数据截止日期2024年8月28日,黑人患者中位随访40·3个月(95% CI 38·3-42·3),白人患者43·9个月(95% CI 43·0-45·1)。
  • 黑人患者较白人患者治疗中断时间更长(2年未调整率10·7% [95% CI 9·8-11·7] vs 8·6% [95% CI 8·2-9·0];调整HR 0·91,95% CI 0·87-0·95,p<0·0001)。
  • 黑人患者与白人患者至下次治疗时间相似(23·5% [95% CI 22·3-24·8] vs 25·6% [95% CI 25·0-26·2];HR 1·00,95% CI 0·95-1·05,p=0·96)。
  • 黑人患者较白人患者总生存略有改善(36·5% [95% CI 35·2-38·1] vs 36·5% [95% CI 35·8-37·1];HR 0·95,95% CI 0·90-0·99,p=0·036)。
  • 黑人患者较白人患者所有级别免疫相关不良事件风险降低(2年未调整率33·1% [95% CI 28·9-37·1] vs 44·1% [95% CI 39·1-48·7];调整HR 0·75,95% CI 0·62-0·90,p=0·0026)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 黑人患者毒性降低的发现需进一步研究以评估其普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Black patients were severely under-represented in the clinical trials that led to the approval of immune checkpoint inhibitors (ICIs) for all cancers. The aim of this study was to characterise the effectiveness and safety of ICIs in Black patients. METHODS: We did a retrospective cohort study of patients in the US Veterans Health Administration (VHA) system's Corporate Data Warehouse containing electronic medical records for all patients who self-identified as non-Hispanic Black or African American (referred to as Black) or non-Hispanic White (referred to as White) and received PD-1, PD-L1, CTLA-4, or LAG-3 inhibitors between Jan 1, 2010, and Dec 31, 2023. Effectiveness outcomes were overall survival, time to treatment discontinuation, and time to next treatment. The safety outcome was the frequency of immune-related adverse events; assessed among a random sample of 1000 Black patients and 1000 White patients, 892 pairs were matched on the basis of baseline characteristics using 1:1 exact matching without replacement. After manual chart review, patients who did not receive ICI therapy or who had inadequate follow-up were excluded. The adjusted effect of race on each effectiveness outcome was assessed in the whole ICI-treated cohort with propensity-weighted Cox regression with robust standard errors. Immune-related adverse events outcomes were analysed in the random matched sample with multivariable Cox regression, adjusting for baseline characteristics. FINDINGS: We identified 26 398 patients, of whom 4943 (18·7%) patients were Black, 21 455 (81·3%) were White, 895 (3·4%) were female, 25 503 (96·6%) were male, 11 859 (45%) had non-small-cell lung cancer, and 26 045 (98·7%) received PD-1 or PD-L1 inhibitors. As of data cutoff (Aug 28, 2024), median follow-up was 40·3 months (95% CI 38·3-42·3) for Black patients and 43·9 months (43·0-45·1) for White patients. Compared with White patients, Black patients had longer time to treatment discontinuation (2-year unadjusted rates 10·7% [95% CI 9·8-11·7] for Black patients vs 8·6% [8·2-9·0] for White patients; adjusted hazard ratio [HR] 0·91, 95% CI 0·87-0·95, p<0·0001), similar time to next treatment (23·5% [22·3-24·8] for Black patients vs 25·6% [25·0-26·2] for White patients; 1·00, 0·95-1·05, p=0·96), and slightly improved overall survival (36·5% [35·2-38·1] for Black patients vs 36·5% [35·8-37·1]; 0·95, 0·90-0·99, p=0·036). 1710 patients (n=862 Black and n=848 White) were analysed for safety outcomes. Compared with White patients, Black patients had a reduced risk of all-grade immune-related adverse events (unadjusted 2-year rate 33·1% [95% CI 28·9-37·1] vs 44·1% [95% CI 39·1-48·7]; adjusted HR 0·75, 95% CI 0·62-0·90, p=0·0026), immune-related adverse events requiring treatment with systemic steroids (0·61, 0·46-0·81, p=0·00051), and immune-related adverse events resulting in permanent ICI discontinuation (0·58, 0·44-0·78, p=0·00024). In exploratory analyses of irAE subtypes, a significant risk reduction in Black patients was found for colitis (0·46, 0·27-0·76, p=0·0026) and hyperthyroidism or hypothyroidism (0·63, 0·44-0·90, p=0·011), and no significant differences were found for any other immune-related adverse event subtypes analysed. Similar results were found in analyses using a steroid-based definition of immune-related adverse events among the entire ICI-treated cohort. INTERPRETATION: Compared with White patients, Black patients had similar ICI effectiveness and lower toxicities among those treated in the national VHA system, potentially reflecting an important difference in the therapeutic ratio (ratio of benefit to harm) of ICIs. Our findings of decreased toxicity among Black patients require further investigation to assess their generalisability. FUNDING: Million Veteran Program, Office of Research and Development, Veterans Health Administration and the LUNGevity foundation.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Miller S, Jiang R, Schipper M, et al. Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study. Lancet Oncol. 2024. PMID: 39551068. doi:10.1016/S1470-2045(24)00528-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。